Teriparatide persistence and tolerance in patients with osteoporosis: Observational data from clinical practice

Joint Bone Spine. 2018 Oct;85(5):641-642. doi: 10.1016/j.jbspin.2018.01.005. Epub 2018 Jan 31.

Authors

Nicolas Taisne¹, Marie-Amélie Mignot¹, Isabelle Legroux², Bernard Cortet², Julien Paccou³

Affiliations

¹ Département de rhumatologie, université de Lille, rue Émile-Laine, 59037 Lille, France.
² Département de rhumatologie, université de Lille, rue Émile-Laine, 59037 Lille, France; PMOI, EA 4490, 59000 Lille, France.
³ Département de rhumatologie, université de Lille, rue Émile-Laine, 59037 Lille, France; PMOI, EA 4490, 59000 Lille, France. Electronic address: [email protected].

PMID: 29407040
DOI: 10.1016/j.jbspin.2018.01.005

No abstract available

Keywords: Corticosteroid-induced osteoporosis; Male osteoporosis; Persistence; Postmenopausal osteoporosis; Teriparatide; Tolerance.

Publication types

Comparative Study
Letter
Observational Study

MeSH terms

Absorptiometry, Photon
Academic Medical Centers
Age Factors
Aged
Aged, 80 and over
Bone Density Conservation Agents / therapeutic use*
Female
France
Humans
Incidence
Male
Middle Aged
Osteoporosis / diagnosis
Osteoporosis / drug therapy*
Osteoporotic Fractures / epidemiology*
Osteoporotic Fractures / prevention & control
Risk Assessment
Severity of Illness Index
Sex Factors
Teriparatide / therapeutic use*
Treatment Outcome

Substances

Bone Density Conservation Agents
Teriparatide